To determine the common gene expression changes governed by the SOC therapies used in ER+ breast cancer, i.e., tamoxifen, fulvestrant and palbociclib, which will further uncover signatures of sensitivity and resistance, we analyzed the Connectivity Map database13. The gene discussed is UBXN11; the disease is breast carcinoma.